4Vote!
PR News Wire (Free subscription) | 11/25/2009
EXTON, Pa., Nov. 25 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists...
4Vote!
PR News Wire (Free subscription) | yesterday
... percent versus 5.6 percent). This boost is due in part to physicians' increased prescribing of Centocor Ortho Biotech's Remicade as a second- or third-line therapy for newly diagnosed patients.
5Vote!
The Philadelphia Business Journal (Free subscription) | 10/28/2009
Morphotek Inc. entered into a license agreement Wednesday with Centocor Ortho Biotech Inc. covering the development and commercialization of an antibody that targets a specific antigen that is over-expressed in cancer patients with a variety of solid tumors. (JNJ)
3Vote!
Contract Pharma Breaking News (Free subscription) | 10/28/2009
Morphotek, Inc. has entered into a license agreement with Centocor Ortho Biotech for the development and commercialization of an antibody targeting solid tumors. Financial terms were not disclosed. Morphotek has been granted an exclusive worldwide license for the development, manufacture and sale of the antibody. Preclinical studies conducted by Centocor have shown that the relevant...
4Vote!
PR News Wire (Free subscription) | 10/28/2009
EXTON, Pa., Oct. 28 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody that targets a tumor-associated antigen over-expressed in many solid tumors.
5Vote!
Red Orbit (Free subscription) | 10/28/2009
EXTON, Pa., Oct. 28 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc.
4Vote!
PR News Wire (Free subscription) | 12/07/2009
BOTHELL, Wash., Dec. 7 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, today announced that it has executed a license and custom cGMP manufacturing agreement with Centocor Research & Development, Inc. The agreement includes the production of a custom variant...
+Vote!
Business Wire (Free subscription) | 11/30/2009
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. (“Centocor”) for the optimization of Centocor’s antibody drug candidates....
+Vote!
PR News Wire (Free subscription) | 12/01/2009
BRIDGEWATER, N.J., Dec. 1 /PRNewswire/ -- Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that it is launching a new initiative to raise awareness of issues affecting women and people of color living with HIV/AIDS. Through a comprehensive campaign including local educational events, media outreach and a new Web site, www.TheGraceStudy.com, the company...
+Vote!
Fiercebiotech (Free subscription) | 11/30/2009
Over the past year Endo's new CEO, David Holveck ( photo ), has been steadily shifting the company's focus from pain management to new therapeutic arenas like oncology, doing $900 million worth of deals. And the CEO says he's far from done with the makeover. With the New Year looming, Holveck, the former CEO of Centocor, tells the Philadelphia Business Journal that he's planning a string of...
4Vote!
PR News Wire (Free subscription) | 11/25/2009
... and DUET-2. INTELENCE is currently marketed in the U.S. by Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P.
5Vote!
The Nashville Business Journal (Free subscription) | 11/24/2009
AmSurg Corp. has appointed noted gastroenterologist John W. Popp Jr. to its board of directors. Popp is clinical professor of medicine at the University of South Carolina School of Medicine and a medical director for Centocor, Inc., which provides biomedicines for immune disorders. Since 1998, the Yale Medical School and Vanderbilt graduate has served on the board of trustees for the American...
4Vote!
Business Wire (Free subscription) | 11/23/2009
NASHVILLE, Tenn.--(BUSINESS WIRE)--AmSurg Corp. (NASDAQ: AMSG), today announced the appointment of John W. Popp, Jr., M.D. to its Board of Directors. Dr. Popp is Clinical Professor of Medicine at the University of South Carolina School of Medicine and a Medical Director for Centocor, Inc., a unit of Johnson and Johnson, which provides innovative biomedicines for debilitating immune disorders....
3Vote!
IPBiz (Free subscription) | 11/15/2009
Bruce Lehman, who as Commissioner of Patents & Trademarks (aka Director) opposed the creation of a publicly-available patent database, weighed in on patent reform in commenting on the case Centocor v. Abbott: So, in the Centocor case, some 18 years of scientific discovery and complex damage calculations came before the court in fewer than four days of testimony. It is little wonder...
5Vote!
Red Orbit (Free subscription) | 11/24/2009
From 2001 to 2004, Mr. Orwin achieved increasing responsibility at Johnson & Johnson, up to Franchise Vice President, Oncology Franchise at Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P. His previous experience includes the positions of Senior Director, Oncology Marketing at Alza Pharmaceuticals (acquired by Johnson & Johnson); Vice President, Marketing at Sangstat...
